FORTISFortis Healthcare Limited
Healthcare · Medical Care Facilities · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, and haematology areas. It also provides services in the areas of infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, organ transplant, rheumatology, thoracic surgery, transfusion medicine, urology, medical generics, endocrine surgery, and other support specialties, as well as treat infectious diseases. The company's healthcare verticals comprise hospitals, diagnostics, tertiary and quaternary care, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 17.8% YoY
- • Profit growth: 44.3% YoY
- • Debt/Equity: 0.34
- • MACD: fresh bullish crossover
- • Trend strength (ADX): 45
- • Volatility: 26% annualized
- • RSI Oversold Reversal signal (setup quality 56%)
Bull case
- • Revenue growth: 17.8% YoY
- • Profit growth: 44.3% YoY
- • Debt/Equity: 0.34
- • MACD: fresh bullish crossover
Bear case
- • Promoter holding: 35.2%
- • Dividend yield: 0.11%
- • RSI: 33
- • Price vs EMA21: below
Key risks
- • Momentum is fading versus the broader market
- • Promoter holding: 35.2%
- • Dividend yield: 0.11%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹22.54). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.